ScripPharma executives no longer ask whether AI is important in their industry – that much is certain, and it is already ubiquitous. As Lamine Mbow , global head of discovery research at Boehringer Ingelh
ScripGSK is still in the race to bring an mRNA-based flu vaccine to market after scoring a Phase II trial success. The UK-headquartered firm will now take its candidate, GSK4382276A, into Phase III, thoug
ScripTaking Stock Of Expensive Biotech I took the decision recently to take profits from much of my exposure to biotech companies in the exchange-traded funds that are based on the NASDAQ Biotech Index (NB
ScripGSK is investing a further €400m ($430m) in its alliance with CureVac in order to compete with the frontrunners in the mRNA vaccines field. The UK-based company has seen a renaissance in its vaccin